走进走出In drug rearch and development, the patient is the focus. The mission for nova is to help the patient overcome a dia and improve their quality of life. The drug development process is designed to ensure that innovative new medicines are effective ,safe and available for patients in the shortest possible time.
Chapter 1
金鸡石Target Discovery
延吉美食The first step in drug development is to discover the best targets for treating or prevent a dia. Targets are usually proteins in the patient’s body which are associated with the dia or proteins in microorganisms causing a dia. The challenge is to identify which proteins are relevant and more importantly confirm their role in a dia. Increasingly, nova focus on understanding cellular networks of proteins or pathways. A single protein may transmit messages to veral other proteins, sometimes in multiple pathways affecting their function. Knowing how the pathways work and interact helps to identify the most appropriate target for a drug. The pathway approach allows nova to better understand the
mechanisms of a dia. This knowledge together with the desire to address unmet medical needs determines the primaries in target discovery.
Chapter 2
Drug Discovery
In drug discovery, veral methods like high-throughput screening and computer-bad design are ud to find chemical compounds or biologics that bind to the identified target. If a compound modulates the target in a way that is expected to alter the dia. This so-called hit will be refined to improve its safety and effectiveness, eventually becoming a drug candidate. Discovering and bringing one new drug to the market typically takes an average of fourteen years of rearch and clinical development efforts and cost around two billion us dollars. Of 10,000 or more hits tested in early drug discovery only one may eventually lead to a drug that reaches the market.
Chapter 3
免费论文
Safety and Drug Metabolism
In the late preclinical stage, further experiments are conducted on the drug candidate to ensure it is safe for patients and has the required pharmacokinetic properties like appropriate absorption and metabolism by the human body. The experiments are executed with extraordinary diligence to minimize any risks to human test subjects. Animals play a critical role in the drug discovery process as well. Although much rearch and development can be done using various experiments or using computers, complex dia mechanisms can often only be understood though the u of animal studies. Also, governments and regulatory authorities require that medicines be tested in animals before they are tested in humans. Nova keeps this rearch as limited as possible had always ensures that animal rearch is scientifically acceptable according to current standards and regulations. For the reasons, nova continues to u animals in its quest to find innovative safe and life-saving medicines for patients. At the same time, nova is committed to refining, reducing and replacing the u of animals in rearch and upholding the highest standards in animal welfare.
蜈支洲岛简介Chapter 4
Clinical Pha I-II
Clinical trail programs consist of veral phas, each of which is focud on evaluating drug safety and effectiveness or efficacy. Information on ongoing clinical trials can be found at v. In pha I of clinical trials, the drug is usually tested in healthy volunteers to determine its safety and pharmacokinetics. In pha II, the drug is given to a group of about 100 to 250 patients with the dia to re-evaluate its efficacy and to determine the optimal do. In addition, the safety of the drug and its side effects are evaluated as the may be different in patients compared to the healthy volunteers tested in pha one. Nova also conduct trials called proof of concept or poc trials which are often a mix of pha I and pha II studies. A group of well-defined patients is treated with the drug candidate to provide an early indication whether it actually affects the target in the intended way or has a beneficial impact on the dia. The studies allow nova to rapidly invest resources on drug compounds which are effective and safe. This way, th
e appropriate medicines can reach the patient’s faster. The data from pha I and pha II studies provide the scientific confidence necessary to continue the development of the compound in larger clinical trials.
Chapter 5
Clinical Pha III
小狗日记In pha III clinical trials, 1000 to 3000 or even more patients are recruited for rearch with the investigational drug. Pha III clinical trials are undertaken to confirm the effectiveness of the new drug, monitor side effects, compare it to establish treatments, and gather additional information to allow the drug to be ud safely.
古诗谜
Chapter 6
公司管理层培训Registration & Pharmacovigilance
To bring a new medicine on the market every new drug needs to be registered by the hea
lth authority. Data from all clinical trials are collected and compiled into a document called registration dossier. The registration dossier will include efficacy and safety data to support the final intended u of the drug. The dossier is then customized for different regions and countries around the world to meet the requirements of health authorities. This is a crucial step to ensure that patients all over the globe can access the innovative medicines that have made it through the complex drug discovery and development process. Once the registration dossier is approved and the product is launched. Several activities will continue like drug safety monitoring which is mandatory. Post authorization safety updates, annual reports and any additional information required by the health authority must be provided at the defined intervals as long as the drug remains on the market. Often pha IV clinical trials are initiated to gather additional data not collected in the pha III program. This may include efficacy, safety, additional benefit and risk information as well as pharmacoeconomic data. Our mission is to provide safe and effective treatments that benefit patients and improve the quality of their lives.
